• Please log in or register to access this feature.

Original Report

Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program†

  1. Robert J. Cluxton Jr PharmD1,4,
  2. Zili Li MD, MPH2,
  3. Pamela C. Heaton PhD, RPh1,*,
  4. Sheila R. Weiss PhD3,
  5. Ilene H. Zuckerman PharmD3,
  6. Charles J. Moomaw PhD4,
  7. Van Doren Hsu PharmD3,
  8. Evelyn M. Rodriguez MD, MPH3

Article first published online: 15 NOV 2004

DOI: 10.1002/pds.1048

Issue

Pharmacoepidemiology and Drug Safety

Pharmacoepidemiology and Drug Safety

Volume 14, Issue 1, pages 1–9, January 2005

Additional Information

How to Cite

Cluxton, R. J., Li, Z., Heaton, P. C., Weiss, S. R., Zuckerman, I. H., Moomaw, C. J., Hsu, V. D. and Rodriguez, E. M. (2005), Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program. Pharmacoepidem. Drug Safe., 14: 1–9. doi: 10.1002/pds.1048

Author Information

  1. 1

    College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA

  2. 2

    Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA

  3. 3

    Center on Drugs and Public Policy, School of Pharmacy, University of Maryland, Baltimore, MD, USA

  4. 4

    Institute for Health Policy and Health Services Research, University of Cincinnati Medical Center, Cincinnati, OH, USA

*College of Pharmacy, University of Cincinnati, 3223 Eden Avenue, Cincinnati, OH 45267-0004, USA.

  1. †

    The views expressed are those of the authors and do not necessarily represent those of, nor imply endorsement from, the Food and Drug Administration of the U.S. Government, academic institutions or the drug industry.

Publication History

  1. Issue published online: 13 DEC 2004
  2. Article first published online: 15 NOV 2004
  3. Manuscript Accepted: 1 OCT 2004
  4. Manuscript Revised: 24 SEP 2004
  5. Manuscript Received: 11 AUG 2004

Funded by

  • Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (201K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Get PDF (201K)